ATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today CE Mark approval for its FemHSG^™ Catheter, further expanding the Company's portfolio in Europe through commercial partners. Designed to support procedural efficiency during the initial fertility workup, the FemHSG Catheter is used together with the Company's FemVue device for in-office ultrasound-based evaluation.

Infertility impacts millions of women worldwide, and because appropriate diagnosis is essential prior to treatment, Femasys is focused on equipping OB/GYNs and other women's health practitioners with in-office solutions. The newly CE Mark approved FemHSG Catheter and FemVue device are designed to support a comprehensive initial fertility workup. FemaSeed^®, the Company's first-line fertility treatment, represents the next step in the care pathway, supporting access to earlier, more cost-effective intervention.

"We believe improving access to timely, affordable fertility diagnosis and intervention can have a meaningful impact on patient care worldwide," said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. "The addition of FemHSG Catheter further strengthens our growing fertility portfolio and provides OB/GYNs the opportunity to expand in-office fertility services with efficient, accessible solutions."

About FemHSG Catheter

FemHSG^™ Catheter is designed for use in office-based fertility evaluation procedures. The catheter features a small-profile design with an accommodating larger balloon intended to address varying uterine cavity sizes without catheter exchange. Together, FemHSG catheter and FemVue^® enable a comprehensive ultrasound-based diagnostic assessment of the uterine cavity and fallopian tubes efficiently within existing physician workflow.

About Femasys

Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys' fertility portfolio includes FemaSeed^® Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment used with the CLIA waived FemSperm^® sperm preparation and analysis product line; FemVue^®, a device enabling ultrasound-based fallopian tube assessment; and FemHSG^™ Catheter, used with FemVue for comprehensive fertility workup. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rate of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.¹

FemBloc^® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec^®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrate compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.²For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is ongoing.

Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

References

¹Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

²Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "pending," "intend," "believe," "suggests," "potential," "hope," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts:

IR@femasys.com

Media@femasys.com

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter